Related Experiment Videos
Advances in antithrombotic therapy: novel agents
A G Turpie1, J I Weitz, J Hirsh
1McMaster University, Hamilton, Ontario, Canada.
Thrombosis and Haemostasis
|July 1, 1995
Summary
Direct thrombin inhibitors show promise for acute coronary syndromes and deep vein thrombosis prevention. Further dose-finding studies are crucial for safe and effective use in clinical trials.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Direct thrombin inhibitors are increasingly evaluated for cardiovascular conditions.
- Recombinant hirudin shows a narrow safety window with thrombolytics and aspirin in acute myocardial infarction.
Purpose of the Study:
- To review the clinical evaluation and potential of direct thrombin inhibitors.
- To highlight the need for further research into optimal dosing and safety.
Main Methods:
- Review of recent clinical reports and efficacy data.
- Analysis of safety and therapeutic potential in acute coronary syndromes and thrombosis prevention.
Main Results:
- Direct thrombin inhibitors demonstrate efficacy in acute unstable angina and non-Q-wave infarction.
- Recombinant hirudin requires careful safety assessment, especially with combination therapies.
- Potential for deep vein thrombosis prevention in high-risk surgical patients.
Conclusions:
- Direct thrombin inhibitors hold significant potential for managing acute coronary ischaemia.
- Dose-finding studies are essential to establish safe regimens for large-scale clinical trials.
- Further research is needed on novel anticoagulants currently in development.